Global EditionASIA 中文雙語Fran?ais
    China
    Home / China / Health

    Study finds virus antibodies last at least 12 months

    By WANG XIAOYU | CHINA DAILY | Updated: 2021-07-08 09:27
    Share
    Share - WeChat
    A recovering pneumonia patient gives a thumbs-up to medical workers at Wuhan University's Zhongnan Hospital, in early 2020. [GAO XIANG/FOR CHINA DAILY]

    Antibodies against the novel coronavirus can last for at least 12 months in more than 70 percent of recovered COVID-19 patients, a study published by Chinese researchers on Tuesday shows.

    The finding adds to growing evidence that vaccination, which elicits an immune response in a way similar to how a live virus triggers human bodies to generate antibodies, can "effectively restrict the spread of SARS-CoV-2", the study said.

    The study, published online by Nature Communications, was conducted by China National Biotech Group, a Sinopharm subsidiary, and the National Research Center for Translational Medicine at Shanghai Jiao Tong University.

    Researchers collected 1,782 convalescent plasma samples from 869 recovered COVID-19 patients in Wuhan, Hubei province, within 12 months of diagnosis, and tested them for the presence and amount of RBDIgG, a type of antibody that indicates the strength of immunity against the virus.

    Testing results showed that in nine months, levels of the antibody dropped to 64.3 percent of the initial level when they contracted the virus, and then stabilized into the 12th month.

    "It shows that once immune responses against the novel coronavirus are induced in human bodies, antibody levels can be maintained for quite a long time," China National Biotech Group said in an article on its WeChat account on Wednesday.

    The study found that the antibody response was significantly stronger in male participants than in their female counterparts in the early stages of infection, but the difference dwindled over time and nearly disappeared in 12 months.

    Among participants aged 18 to 55, the older ones developed higher antibody levels, it added.

    The company said the study is the longest-running research aimed at examining the persistence of antibody response in recovered COVID-19 patients.

    The finding was published as mass vaccination in China proceeds smoothly, with the country stepping up vaccine donations or sales overseas.

    As of Tuesday, about 1.3 billion doses of vaccines had been administered nationwide, the National Health Commission said on Wednesday.

    China National Biotech Group added that the study will help improve understanding of the immunological memory elicited by the virus, and provide guidance on future research into vaccine-induced immunity and future vaccination policies in China and abroad.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    欧美日韩v中文字幕| 无码av中文一二三区| 中文字幕精品无码久久久久久3D日动漫| 国产乱码精品一区二区三区中文| 老司机亚洲精品影院无码| 超碰97国产欧美中文| 亚洲人成影院在线无码观看| 无码日韩精品一区二区免费 | 亚洲精品无码精品mV在线观看| 超清无码无卡中文字幕| 成在线人AV免费无码高潮喷水| 亚洲精品无码乱码成人| 天堂网www中文天堂在线| 亚洲日韩VA无码中文字幕| 日韩免费无码视频一区二区三区| 中文字幕在线观看一区二区| 久久久久成人精品无码中文字幕 | 亚洲桃色AV无码| 一级中文字幕免费乱码专区| 人妻少妇久久中文字幕一区二区 | 成人无码小视频在线观看| 无码人妻精品一区二区三区久久| 中文字幕无码播放免费| 日韩中文字幕在线| A最近中文在线| 亚洲精品无码成人片在线观看| 国产成人无码精品久久久免费| 欧洲成人午夜精品无码区久久| 亚洲精品无码国产| 亚洲∧v久久久无码精品| 亚洲AV无码久久| 日日摸日日踫夜夜爽无码| 无码中文av有码中文a| 性无码一区二区三区在线观看| 亚洲色无码专区在线观看| 亚洲热妇无码AV在线播放| 亚洲精品无码久久久久去q| 亚洲国产精品无码久久久秋霞2| 一区二区三区无码视频免费福利 | 精品少妇人妻av无码久久| 国产亚洲人成无码网在线观看|